Compare FTK & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | GOSS |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.1M | 615.7M |
| IPO Year | 1997 | 2018 |
| Metric | FTK | GOSS |
|---|---|---|
| Price | $16.57 | $2.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $20.00 | $8.83 |
| AVG Volume (30 Days) | 232.9K | ★ 5.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 440.00 | 78.81 |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $136,092,000.00 | $114,701,000.00 |
| Revenue This Year | $20.30 | N/A |
| Revenue Next Year | $11.14 | $6.41 |
| P/E Ratio | $22.29 | ★ N/A |
| Revenue Growth | ★ 214.53 | N/A |
| 52 Week Low | $6.05 | $0.76 |
| 52 Week High | $20.09 | $3.87 |
| Indicator | FTK | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 34.41 |
| Support Level | $16.88 | $2.24 |
| Resistance Level | $17.98 | $2.50 |
| Average True Range (ATR) | 1.04 | 0.20 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 49.71 | 3.80 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.